ERBB2 and breast carcinoma: Further, HER2 overexpression and, more recently, an uncovered higher programmed death ligand 1 (PD-L1) expression in HER2+ and TNBC [16], along with the occurrence of germline breast cancer (gBRCA1/2) genetic defects and homologous recombination deficiency (HRD) in the latter, suggest both are suitable for an immunotherapeutic strategy.